Google SSO gives you the quickest path into the IIPLA newsroom, your reading access, and member-level continuity across articles. The full login page is still available if you prefer another option.
Foreign Ministry Responds to U.S. 'Priority Foreign Country' Designation, Citing Legal Reforms and International Cooperation
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
The United States Trade Representative has identified Vietnam as a 'priority foreign country' in its annual intellectual property rights report, citing persistent shortcomings in IP protection and enforcement. This marks the first time in over a decade that a country has received this designation, which could lead to…
India, May 02 : India has once again been placed on the United States Trade Representative’s (USTR) “Priority Watch List” in its latest annual review of intellectual property rights (IPR) protection and enforcement. The designation places India among six countries identified by the US as having significant concerns re…
The United States Trade Representative (USTR) has placed Vietnam on its 'priority foreign country' list for intellectual property concerns, marking the first such designation in over a decade. The move, detailed in the USTR's annual report, signals potential for a new trade investigation and highlights ongoing US conc…
The 2026 Special 301 Report highlights Thailand’s proactive enforcement and legislative reforms, though online piracy and patent backlogs remain concerns The 2026 Special 301 Report highlights Thailand’s proactive enforcement and legislative reforms, though online piracy and patent backlogs remain concerns.
The New York State Bar Association has opened registration for its 2025 Fall Intellectual Property Meeting, featuring panels on evolving brand licensing practices, advertising law challenges, and ethical considerations in AI use for legal services. The event, co-sponsored by Akerman LLP, will provide 3.0 MCLE credits…
Zydus Lifesciences Limited has finalized a comprehensive settlement with Astellas Pharma Inc., ending all US patent disputes over the bladder drug Myrbetriq (Mirabegron). The agreement requires Zydus to pay $120 million plus ongoing licensing fees until September 2027, allowing the company to continue marketing its ge…